Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

41 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Impact of preoperative [18F]FDG PET/CT vs. contrast-enhanced CT in the staging and survival of patients with clinical stage I and II non-small cell lung cancer: a 10-year follow-up study.
Lin JT, Li XM, Zhong WZ, Hou QY, Liu CL, Yu XY, Ye KY, Cheng YL, Du JY, Sun YQ, Zhang FG, Yan HH, Liao RQ, Dong S, Jiang BY, Liu SY, Wu YL, Yang XN. Lin JT, et al. Among authors: liao rq. Ann Nucl Med. 2024 Mar;38(3):188-198. doi: 10.1007/s12149-023-01888-z. Epub 2023 Dec 25. Ann Nucl Med. 2024. PMID: 38145431
Neoadjuvant nivolumab with or without platinum-doublet chemotherapy based on PD-L1 expression in resectable NSCLC (CTONG1804): a multicenter open-label phase II study.
Liu SY, Dong S, Yang XN, Liao RQ, Jiang BY, Wang Q, Ben XS, Qiao GB, Lin JT, Yan HH, Yan LX, Nie Q, Tu HY, Wang BC, Yang JJ, Zhou Q, Li HR, Liu K, Wu W, Liu SM, Zhong WZ, Wu YL. Liu SY, et al. Among authors: liao rq. Signal Transduct Target Ther. 2023 Dec 6;8(1):442. doi: 10.1038/s41392-023-01700-4. Signal Transduct Target Ther. 2023. PMID: 38057314 Free PMC article. Clinical Trial.
Erlotinib versus gemcitabine plus cisplatin as neoadjuvant treatment of stage IIIA-N2 EGFR-mutant non-small-cell lung cancer: final overall survival analysis of the EMERGING-CTONG 1103 randomised phase II trial.
Zhong WZ, Yan HH, Chen KN, Chen C, Gu CD, Wang J, Yang XN, Mao WM, Wang Q, Qiao GB, Cheng Y, Xu L, Wang CL, Chen MW, Kang XZ, Yan WP, Liao RQ, Yang JJ, Zhang XC, Liu SY, Zhou Q, Wu YL. Zhong WZ, et al. Among authors: liao rq. Signal Transduct Target Ther. 2023 Feb 24;8(1):76. doi: 10.1038/s41392-022-01286-3. Signal Transduct Target Ther. 2023. PMID: 36823150 Free PMC article. Clinical Trial.
[Correlations of Androgen Receptor Expression with Molecular Subtypes and Clinopathological Features of Invasive Breast Carcinoma of No Special Type in Tibet].
Luo HH, Jiang Y, BIANbazhaxi, Wang Q, NImazhuoma, Wang H, Wei Q, Liao RQ, CIrenquzhen. Luo HH, et al. Among authors: liao rq. Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2022 Dec;44(6):1033-1039. doi: 10.3881/j.issn.1000-503X.14724. Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2022. PMID: 36621794 Free article. Chinese.
Deep learning-based growth prediction for sub-solid pulmonary nodules on CT images.
Liao RQ, Li AW, Yan HH, Lin JT, Liu SY, Wang JW, Fang JS, Liu HB, Hou YH, Song C, Yang HF, Li B, Jiang BY, Dong S, Nie Q, Zhong WZ, Wu YL, Yang XN. Liao RQ, et al. Front Oncol. 2022 Oct 12;12:1002953. doi: 10.3389/fonc.2022.1002953. eCollection 2022. Front Oncol. 2022. PMID: 36313666 Free PMC article.
PD-1/PD-L1 combined with LAG3 is associated with clinical activity of immune checkpoint inhibitors in metastatic primary pulmonary lymphoepithelioma-like carcinoma.
Zhong YM, Yin K, Chen Y, Xie Z, Lv ZY, Yang JJ, Yang XN, Zhou Q, Wang BC, Zhong WZ, Gao LL, Zhou WB, Chen J, Tu HY, Liao RQ, Zhang DK, Zhang SL, Lu DX, Zheng HB, Zhang HH, Wu YL, Zhang XC. Zhong YM, et al. Among authors: liao rq. Front Immunol. 2022 Oct 3;13:951817. doi: 10.3389/fimmu.2022.951817. eCollection 2022. Front Immunol. 2022. PMID: 36263036 Free PMC article.
[Clinicopathological Features of Meningiomas in Tibet].
Luo HH, Huo Z, Wang Q, NIma Z, Duo B, Wei Q, DA Z, Wang H, Guo PP, Liao RQ, CIren Q. Luo HH, et al. Among authors: liao rq. Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2022 Aug;44(4):621-627. doi: 10.3881/j.issn.1000-503X.14472. Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2022. PMID: 36065695 Free article. Chinese.
Longitudinal Undetectable Molecular Residual Disease Defines Potentially Cured Population in Localized Non-Small Cell Lung Cancer.
Zhang JT, Liu SY, Gao W, Liu SM, Yan HH, Ji L, Chen Y, Gong Y, Lu HL, Lin JT, Yin K, Jiang BY, Nie Q, Liao RQ, Dong S, Guan Y, Dai P, Zhang XC, Yang JJ, Tu HY, Xia X, Yi X, Zhou Q, Zhong WZ, Yang XN, Wu YL. Zhang JT, et al. Among authors: liao rq. Cancer Discov. 2022 Jul 6;12(7):1690-1701. doi: 10.1158/2159-8290.CD-21-1486. Cancer Discov. 2022. PMID: 35543554 Free PMC article.
41 results